EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M Apovian, Shagun Bindlish, Jonathan Bonnet, W Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta und 6 weitere

Obesity · 2025-08 · 33 (8) · 1475-1503

DOI: 10.1002/oby.24336 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 30.05.2025. Verfasst von Dariush Mozaffarian und 17 weiteren Autor:innen. Beteiligte Einrichtung: Food is Medicine Institute, Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity. Die Arbeit wurde bisher 160-mal zitiert (Crossref) und nennt 301 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Duke Clinical and Translational Science Institute (RK), NIDDK NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glucagon‐like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP‐1s) are shifting the treatment landscape for obesity. However, real‐world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP‐1 efficacy, equitable results, and cost‐effectiveness.

Objectives

We aimed to identify pragmatic priorities for nutrition and other lifestyle interventions relevant to GLP‐1 treatment of obesity for the practicing clinician.

Methods

An expert group comprising multiple clinical and research disciplines appraised the scientific literature, informed by expert knowledge and clinical experience, to identify and summarize relevant topics, priorities, and emerging directions.

Results

GLP‐1s reduce body weight by 5% to 18% in trials, with modestly lower effects in real‐world analyses, and multiple demonstrated clinical benefits. Challenges include side effects, especially gastrointestinal; nutritional deficiencies due to calorie reduction; muscle and bone loss; low long‐term adherence with subsequent weight regain; and high costs with resulting low cost‐effectiveness. Numerous practice guidelines recommend multicomponent, evidence‐based nutritional and behavioral therapy for adults with obesity, but use of such therapies with GLP‐1s is not widespread. Priorities to address this include: (a) patient‐centered initiation of GLP‐1s, including goals for weight reduction and health; (b) baseline screening, including usual dietary habits, emotional triggers, disordered eating, and relevant medical conditions; (c) comprehensive exam including muscle strength, function, and body composition assessment; (d) social determinants of health screening; (e) and lifestyle assessment including aerobic activity, strength training, sleep, mental stress, substance use, and social connections. During GLP‐1 use, nutritional and medical management of gastrointestinal side effects is critical, as is navigating altered dietary preferences and intakes, preventing nutrient deficiencies, preserving muscle and bone mass through resistance training and appropriate diet, and complementary lifestyle interventions. Supportive strategies include group‐based visits, registered dietitian nutritionist counseling, telehealth and digital platforms, and Food is Medicine interventions. Drug access, food and nutrition insecurity, and nutrition and culinary knowledge influence equitable obesity management with GLP‐1s. Emerging areas for more study include dietary modulation of endogenous GLP‐1, strategies to improve compliance, nutritional priorities for weight maintenance post‐cessation, combination or staged intensive lifestyle management, and diagnostic criteria for clinical obesity.

Conclusions

Evidence‐based nutritional and lifestyle strategies play a pivotal role to address key challenges around GLP‐1 treatment of obesity, making clinicians more effective in advancing their patients' health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsObesityHumansCost-Benefit AnalysisLife StyleUnited StatesWeight Loss

Substanzen

Glucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Food is Medicine Institute, Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, USA.
  • Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Division of Cardiology, University of Florida, Gainesville, Florida, USA.
  • Enara Health, San Mateo, California, USA.
  • Center for Weight Management and Wellness, Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Touro University and One Medical, Dublin, California, USA.

Förderung

  • Duke Clinical and Translational Science Institute (RK)
  • NIDDK NIH HHS
  • NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., Gulati, M., Gupta, A., Horn, D., Kane, R. M., Saluja, J., Sannidhi, D., Stanford, F. C., & Callahan, E. A. (2025). Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity, 33(8), 1475-1503. https://doi.org/10.1002/oby.24336

Vancouver

Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S, et al. Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. doi:10.1002/oby.24336

BibTeX
@article{Mozaffarian2025,
  author = {Mozaffarian, Dariush and Agarwal, Monica and Aggarwal, Monica and Alexander, Lydia and Apovian, Caroline M and Bindlish, Shagun and Bonnet, Jonathan and Butsch, W Scott and Christensen, Sandra and Gianos, Eugenia and Gulati, Mahima and Gupta, Alka and Horn, Debbie and Kane, Ryan M and Saluja, Jasdeep and Sannidhi, Deepa and Stanford, Fatima Cody and Callahan, Emily A},
  title = {Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {8},
  pages = {1475--1503},
  doi = {10.1002/oby.24336}
}
Kostenlos starten →